Abstract
Lentiviral vectors (LVs) represent powerful vaccines for antitumor immunotherapy since they can deliver tumor-associated antigens together with intrinsic stimulatory signals to antigen-presenting cells (APCs) in situ. The use of broad tropism LVs, which infect both APCs as well as non-APCs, brings along several concerns. Regarding antitumor immunotherapy these include that infection of different APC-subtypes could lead to a dispersed immune response and that transduction of long-lived non-APCs increases the risk for insertional mutagenesis. Therefore we propose to target LVs to specific APC-subtypes as we hypothesize that this could increase both their safety and efficacy profile.
To generate APC-subtype targeted LVs, we developed the Nanobody display technology, which allows the inclusion of a fusogenic but binding-defective envelope glycoprotein together with an APC-specific Nanobody on the LVs’ surface. We characterized their tranduction profile after in vivo or ex vivo intranodal injection of murine and human lymph nodes respectively. Furthermore, their potential to stimulate an ovalbumin specific immune response was evaluated using several immunological assays.
First, we demonstrated specific transduction of murine and human short-lived APC-subtypes, which was also reflected in their short transgene expression period compared to the broad tropism LVs. Next we evaluated their immune stimulatory potential and observed that targeting doesn’t improve their potential to induce functional T cells, which was reflected in their reduced ability to induce a therapeutic benefit. Moreover, we added the IL-12 gene to the LV-cargo to improve their immune stimulatory potential. However, this had only a minor impact on the immunogenicity of the targeted LVs whereas it boosted the performance of the broad tropism LVs.
In conclusion we show that the Nanobody display technology allows the generation of APC-subtype specific LVs with a safer kinetic profile. However, we also showed that the transduction of non-APCs is of paramount importance to induce an adequate therapeutic response.
To generate APC-subtype targeted LVs, we developed the Nanobody display technology, which allows the inclusion of a fusogenic but binding-defective envelope glycoprotein together with an APC-specific Nanobody on the LVs’ surface. We characterized their tranduction profile after in vivo or ex vivo intranodal injection of murine and human lymph nodes respectively. Furthermore, their potential to stimulate an ovalbumin specific immune response was evaluated using several immunological assays.
First, we demonstrated specific transduction of murine and human short-lived APC-subtypes, which was also reflected in their short transgene expression period compared to the broad tropism LVs. Next we evaluated their immune stimulatory potential and observed that targeting doesn’t improve their potential to induce functional T cells, which was reflected in their reduced ability to induce a therapeutic benefit. Moreover, we added the IL-12 gene to the LV-cargo to improve their immune stimulatory potential. However, this had only a minor impact on the immunogenicity of the targeted LVs whereas it boosted the performance of the broad tropism LVs.
In conclusion we show that the Nanobody display technology allows the generation of APC-subtype specific LVs with a safer kinetic profile. However, we also showed that the transduction of non-APCs is of paramount importance to induce an adequate therapeutic response.
| Original language | English |
|---|---|
| Title of host publication | Third PhD Day at VUB, Jette, Belgium |
| Publication status | Published - 18 Apr 2014 |